In this uncontrolled, exploratory study, 77 adults hospitalized with confirmed COVID-19 were treated with either nebulized IFN-α2b (5 mU b.i.d.), arbidol (200 mg t.i.d.)or a combination of IFN-α2b plus arbidol. The gene discussed is IFNA2; the disease is COVID-19.